OncoNano is a clinical-stage oncology company working to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano's ON-BOARD™ platform exploits the highly acidic tumor microenvironment, a byproduct of cancer metabolism, to maximize the intratumoral delivery of its therapeutic cargoes. ON-BOARD™ ultra pH-sensitive polymeric micelles protect payloads from systemic exposure and target tumors by responding to tumor acidity– a well-established metabolic hallmark shared by most solid tumors regardless of tissue origin and pathology. The simplicity of the micelle approach eliminates the need for more complex surface biomarkers that may limit therapeutic utility due to expression heterogeneity. Currently with one clinical stage and multiple pre-clinical assets, OncoNano is generating a robust oncology pipeline to advance more precise therapies and better patient outcomes.